| Ong, Tiong |
NCT05687591: Left Atrial Appendage Occlusion With The Amplatzer Amulet Device: The Southeast Asia Observational Study |
|
|
| Recruiting | N/A | 100 | RoW | Amplatzer Amulet Left Atrial Appendage Occlusion Device | Sarawak Heart Centre, InnoSignum, Abbott | Atrial Fibrillation | 10/24 | 10/24 | | |
REVERSE, NCT05846893: Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease |
|
|
| Recruiting | N/A | 1436 | RoW | SeQuent® Please NEO drug-coated balloon catheter, Current-generation drug-eluting stent | B. Braun Medical Industries Sdn. Bhd., B. Braun Melsungen AG, Ulsan University Hospital, European Cardiovascular Research Center, Seoul National University Hospital, Universität des Saarlandes | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Coronary Stenosis, De Novo Stenosis | 10/26 | 09/28 | | |
| Chen, Jen-Shi |
| Active, not recruiting | 2 | 34 | RoW | CVM-1118, TRX-818 | TaiRx, Inc. | Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma | 09/24 | 12/25 | | |
NCT05156203: Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | T-1301 Capsules | Taivex Therapeutics Corporation | Advanced Solid Tumor, Lymphoma | 01/27 | 12/27 | | |
| Recruiting | 1 | 78 | Japan, RoW | Pimitespib, TAS-116, Imatinib, Sunitinib | Taiho Pharmaceutical Co., Ltd. | Gastrointestinal Stromal Tumors | 12/25 | 12/25 | | |
| Liu, Chen-Hua |
NCT02149368: Liver Test Study of Using JKB-122 in HCV-Positive Patients |
|
|
| Recruiting | 2 | 148 | RoW | JKB-122, Placebo | Jenken Biosciences Inc., TaiwanJ Pharmaceuticals Co., Ltd | Chronic Hepatitis C | 08/16 | | | |
| Sticherling, Michael |
| Recruiting | 2/3 | 474 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen, Biogen Idec Research Limited | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | 10/26 | 12/27 | | |
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis |
|
|
| Completed | 1 | 24 | Europe, US | CDX-0159, barzolvolimab, Normal saline | Celldex Therapeutics | Prurigo Nodularis | 07/23 | 07/23 | | |
|
| Yang, Sheng-Shun |
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement |
|
|
| Recruiting | 2 | 120 | Europe, Japan, US, RoW | TAS-120, Futibatinib | Taiho Oncology, Inc. | Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement | 06/25 | 06/26 | | |
NCT05276297 / 2021-003567-10: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy |
|
|
| Active, not recruiting | 2 | 184 | Europe, RoW | GSK3228836, Bepirovirsen, GSK3528869A, Control | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 02/26 | 02/26 | | |
NCT03866187 / 2017-001452-55: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection |
|
|
| Terminated | 1/2 | 135 | Europe, RoW | ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 10/24 | 10/24 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
NCT06277037: Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) |
|
|
| Recruiting | N/A | 50 | Europe, US, RoW | Non-interventional | Arbutus Biopharma Corporation | Long Term Follow-up | 08/29 | 10/29 | | |
| Dai, Chia-Yen |
NCT02149368: Liver Test Study of Using JKB-122 in HCV-Positive Patients |
|
|
| Recruiting | 2 | 148 | RoW | JKB-122, Placebo | Jenken Biosciences Inc., TaiwanJ Pharmaceuticals Co., Ltd | Chronic Hepatitis C | 08/16 | | | |
NCT04133259: Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients |
|
|
| Recruiting | 2 | 44 | RoW | Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, HLX10 for Injection, HLX10, Nucleoside/nucleotide analogues, Entecavir, Tenofovir disoproxil fumarate | Henlix, Inc | Hepatitis B, Chronic | 04/22 | 07/22 | | |
NCT05494528: Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy |
|
|
| Recruiting | N/A | 90 | RoW | Ropeginterferon alfa-2b, P1101, Entecavir | National Taiwan University Hospital, PharmaEssentia | Chronic Hepatitis B Virus Infection | 12/23 | 12/24 | | |
| Bascom, Rebecca |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 698 | Canada, US, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 11/27 | 11/27 | | |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
| Boom, LN |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Untch, Michael |
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label |
|
|
| Recruiting | 4 | 108 | Europe | Ontruzant, SB3, Chemotherapy, Pertuzumab | Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd. | Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer | 04/23 | 07/23 | | |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency ( |
|
|
| Active, not recruiting | 2 | 11 | Europe | Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza | Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC | Malignant Neoplasm of Breast, Breast Cancer | 01/25 | 02/26 | | |
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer |
|
|
| Recruiting | 2 | 220 | Europe | Giredestrant, Triptorelin, Anastrozole | ETOP IBCSG Partners Foundation, Hoffmann-La Roche | Breast Cancer | 06/26 | 06/26 | | |
| Chen, Yuh-Min |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC |
|
|
| Withdrawn | 2 | 80 | Europe, RoW | YH001 + Toripalimab | Eucure (Beijing) Biopharma Co., Ltd | HCC, NSCLC Stage IIIB, NSCLC Stage IV | 12/24 | 03/25 | | |
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation |
|
|
| Recruiting | 2 | 40 | US, RoW | ABN401 | Abion Inc | Advanced Solid Tumors | 04/25 | 08/25 | | |
| Active, not recruiting | 2 | 240 | Europe, US, RoW | CAB-AXL-ADC, BA3011, PD-1 inhibitor | BioAtla, Inc., BioAtla Inc. | Non-Small-Cell Lung Cancer | 08/25 | 08/25 | | |
| Active, not recruiting | 1/2 | 332 | Canada, Japan, US, RoW | BLU-451, Carboplatin, Pemetrexed | Blueprint Medicines Corporation | Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, EGFR Exon 20 Mutation, EGFR Exon 20 Insertion Mutation, EGFR Activating Mutation, Antineoplastic Agents, Metastatic Lung Cancer, Brain Metastases, EGFR-mutated NSCLC, EGFR Atypical Mutations, Including G719X and L861Q | 07/24 | 07/26 | | |
| Wang, Chen |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05506176: A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 |
|
|
| Completed | 2/3 | 1208 | RoW | SIM0417, Simnotrelvir, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 | 01/23 | 03/23 | | |
NCT05761028: A Study of CM310 in Subjects With Moderate to Severe Asthma |
|
|
| Recruiting | 2/3 | 600 | RoW | CM310, Placebo | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Moderate to Severe Asthma | 05/32 | 05/32 | | |
NCT05186909: A Study of CM310 in Subjects With Moderate to Severe Asthma |
|
|
| Completed | 2 | 52 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Asthma | 09/23 | 09/23 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China |
|
|
| Completed | N/A | 1507 | RoW | Prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 11/22 | 02/23 | | |
| Vidal, Oscar Juan |
| Active, not recruiting | 3 | 511 | Europe, US, RoW | HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI) | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Limited-Stage Small Cell Lung Cancer | 07/25 | 12/26 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Terminated | 2 | 3 | Europe, US, RoW | KRT-232, navtemadlin | Kartos Therapeutics, Inc. | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | 08/22 | 08/22 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 186 | Europe, Canada, US, RoW | inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta | iTeos Therapeutics, iTeos Belgium SA | Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer | 04/25 | 05/25 | | |
AMBER, NCT06068153: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC |
|
|
| Withdrawn | 2 | 47 | Europe | Sotorasib, Lenvatinib | ETOP IBCSG Partners Foundation, Amgen, Eisai Inc. | Metastatic Non Small Cell Lung Cancer, KRAS G12C | 09/26 | 12/26 | | |
GALLANT-1, NCT05240131 / 2021-003189-11: A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). |
|
|
| Active, not recruiting | 1/2 | 88 | Europe | GB1211, Placebo, Atezolizumab | Galecto Biotech AB, Linical Europe GmbH, Hoffmann-La Roche | Non-Small Cell Lung Cancer | 05/24 | 11/25 | | |
| Terminated | 1/2 | 52 | Europe, US, RoW | NM21-1480 | Numab Therapeutics AG | Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer | 02/24 | 02/24 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) |
|
|
| Recruiting | 1 | 475 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | GlaxoSmithKline | Neoplasms | 08/25 | 02/27 | | |
NCT03850067: A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer |
|
|
| Completed | 1 | 90 | Europe | CC-90011, Cisplatin, Carboplatin, Etoposide, Nivolumab | Celgene | Small Cell Lung Carcinoma | 07/24 | 07/24 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion |
|
|
| Completed | N/A | 76 | Europe | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 09/23 | 09/23 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Not yet recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 08/25 | 08/25 | | |
